We are delighted to announce a successful exit of Noden Pharma to a leading European business in the specialist pharmaceutical sector. The deal returned 6.7x invested capital over a 24-month period, equivalent to 151% IRR.

Umbra Capital Partners acted as sole financial adviser to Stanley Capital on their acquisition of Noden Pharma from US-listed PDL BioPharma in September, 2020.

This was the first acquisition by Stanley Capital as part of a thematic buy-and-build in the specialty pharma space, so the focus was on achieving a financing that was flexible and scalable to allow future acquisitions.

In addition to providing strategic financial and debt advisory, Umbra co-invested in the equity alongside Stanley Capital.

About Umbra Capital Partners LLP

Umbra Capital Partners LLP (Umbra) is a private merchant bank providing advice and capital to mid-market companies. We have particular expertise in raising capital for buy-and-build transactions (sponsor and non-sponsor), fintechs, and dividend recapitalisations.

Our ability to commit capital and roll fees creates alignment with our clients, ensuring optimal solutions for shareholders. Umbra supports individuals throughout the transaction with both corporate finance and wealth management services.

We also provide our wealth management clients with opportunities to access private deals on a co-investment basis alongside Umbra.